Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features
2018
Objective To assess the clinicopathological and therapeutic features of patients with low (≥1000 to Methods We retrospectively and prospectively analysed standardised report forms and medical records of 202 patients from 14 neuromuscular centres. Results Mean age at onset and mean time between symptom onset to last follow-up were respectively 62.6 years (25–91.4) and 8.4 years (0.3–33.3). Anti-MAG antibody titres at diagnosis were low, medium or high in 11%, 51% and 38% of patients. Patients presented with
monoclonal gammopathyof
undetermined significancein 68% of cases. About 17% of patients presented with ‘atypical’ clinical phenotype independently of anti-MAG titres, including acute or chronic sensorimotor
polyradiculoneuropathies(12.4%), and asymmetric or multifocal neuropathy (3%). At the most severe disease stage, 22.4% of patients were significantly disabled. Seventy-eight per cent of patients received immunotherapies. Transient clinical worsening was observed in 12% of patients treated with
rituximab(11/92). Stabilisation after
rituximabtreatment during the 7–12-month follow-up period was observed in 29% of patients. Clinical response to
rituximabduring the 6-month and/or 7–12-month follow-up period was observed in 31.5% of patients and correlated with anti-MAG titre ≥10 000 BTU. Conclusion Our study highlights the extended clinical spectrum of patients with anti-MAG neuropathy, which appears unrelated to antibody titre. Besides, it may also suggest
beneficial useof
rituximabin the early phase of anti-MAG neuropathy.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
40
References
37
Citations
NaN
KQI